Adidas -2-3% Operating profit 563m cons 564.9m, sales ahead
Alstom +0.5% Alstom/Bombardier are only bidders left for E3.7b contract
Ascom +2% Long term targets ahead of investor day look ahead
Axel Sprngr +2% 3Q Sales 801.5m cons 796m, confirms FY forecasts
Beiersdorf +2-3% Q3 organic inline, margin guidance upgraded
Credit Suisse R 3Q net CHF41M, est loss CHF150M
Croda -2% Maintained FY guidance but FX helping
Dufry +1-2% Q3 revs 1.4% ahead, organic growth better
Dialog Semi -1-2% Had pre-announced, Q4 guidance is a little light
Draegerwerk -1-2% EBIT slightly ahead and sales slightly below
DSM +1-2% Q3 EBITDA 323m Cons 310m, Guidance reiterated
Glencore UNCH No's broadly inline small upgrade in marketing guidance
GN Store Nord +2% Organic growth better, guidance confirmed
Fraport -1% Numbers inline guidance small ahead
Genmab +3-5% Guidance raised on strong Darzalex uptake
Howden +2% Solid performance in 2H, on track to meet expectations
Hermes +3% Q3 sales up 8.8% on constant FX vs est +7%
Hochtief M/P Q3 EBT slightly ahead of cons, confirms FY guidance
ING Groep +3-4% PTP at 1.88b cons 1.56b, CET1 at 13.5% vs cons 13.1%
Inmarsat +2-3% Mixed with Maritime weak but Govt & Aviation very strong
Lancashire +3% PBT better, special dividend ahead of expectations
Miners -1% Copper UNCH, Brent +1.85%, Iron Ore UNCH, China +0.95%
Morrison +1% 3Q LFL sales ex-fuel up 1.6%, est up 1.4%
Next -1% CS DOWNGRADE to UNDERPERFORM (Margin worries)
Novo Nord +1% Negative note from Bernstein on Roche's Haemophilia drug
Orpea +1-2% Sales in third quarter increased 16.8%, confident outlook
Randgold -1-2% Guidance challenging, larger mine behind on production
Repsol -2-3% Adj net of 307m, cons of €320m, cashflow weaker
Regus UNCH Marture continues to moderate, stock has been weak
Rheinmetall +2-3% Sales inline, earnings c7.5% ahead, guidance better
Roche -0.5% Negative note from Bernstein on ACE910 which is Haemophilia
Schroders +3-4% AuM and PBT a good beat, inflow encouraging
Scandi Tob -2-3% Q3 revs inline, cuts FY outlook
Shawbrook M/P Net loan growth Q3 is £157m, looking for £300m for FY
Shire +2% Negative note from Bernstein on Roche's Haemophilia drug
Soc Gen +1-2% Q3 net of €1099m cons €886m, beat came from FICC
Swiss Re +2% Net income 22% better vs cons, better performance in P&C
Swisscom -2% Revs ahead, FY16 Guidance Reiterated
Tates +3% Pretax 140m cons circa 125m
Valiant +1-2% 9-month net income CHf81.4m cons 77.3m
Veolia UNCH EBITA 0.6% light, Net 1.7% ahead of cons
Volkswagen +0.5% VW Financial Services raises forecast for 2016
Vonovia +2% LFL rental grwoth +2.8%, Strong valuation uplift